Removal of Human Ether-à-go-go Related Gene (hERG) K+ Channel Affinity through Rigidity: A Case of Clofilium Analogues
Citations Over Time
Abstract
Cardiotoxicity is a side effect that plagues modern drug design and is very often due to the off-target blockade of the human ether-à-go-go related gene (hERG) potassium channel. To better understand the structural determinants of this blockade, we designed and synthesized a series of 40 derivatives of clofilium, a class III antiarrhythmic agent. These were evaluated in radioligand binding and patch-clamp assays to establish structure-affinity relationships (SAR) for this potassium channel. Efforts were especially focused on studying the influence of the structural rigidity and the nature of the linkers composing the clofilium scaffold. It was shown that introducing triple bonds and oxygen atoms in the n-butyl linker of the molecule greatly reduced affinity without significantly modifying the pKa of the essential basic nitrogen. These findings could prove useful in the first stages of drug discovery as a systematic way of reducing the risk of hERG K(+) channel blockade-induced cardiotoxicity.
Related Papers
- HERG potassium channel and drug evaluation(2005)
- Biosynthesis regulation and drug development for human ether-a-go-go related gene potassium channel:research advances(2013)
- → The Roles of Selected Pore Residues in Pharmacological Inhibition of the hERG Potassium Channel by a Minimally Structured Blocker(2017)
- → Inhibition of hERG Channel Trafficking: An Under‐Explored Mechanism for Drug‐Induced QT Prolongation(2009)